Ultragenyx Pharmaceutical Inc.

NasdaqGS:RARE 株式レポート

時価総額：US$4.2b

Ultragenyx Pharmaceutical マネジメント

マネジメント 基準チェック /24

Ultragenyx Pharmaceuticalの CEO はEmil Kakkisで、 Apr2010年に任命され、 の在任期間は 14.58年です。 の年間総報酬は$ 13.08Mで、 6.3%給与と93.7%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の2.91%を直接所有しており、その価値は$ 123.56M 。経営陣と取締役会の平均在任期間はそれぞれ8.9年と8.6年です。

主要情報

Emil Kakkis

最高経営責任者

US$13.1m

報酬総額

CEO給与比率6.3%
CEO在任期間14.6yrs
CEOの所有権2.9%
経営陣の平均在職期間8.9yrs
取締役会の平均在任期間8.6yrs

経営陣の近況

Recent updates

Ultragenyx: Ready For More Growth After Q3 Earnings Beat

Nov 12

Ultragenyx: Excellent Company, Lackluster Stock

Nov 06

We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt

Sep 04
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt

Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective

Aug 22

There's Reason For Concern Over Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Massive 26% Price Jump

Aug 03
There's Reason For Concern Over Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Massive 26% Price Jump

Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being

Jun 12
Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being

Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching

Jun 06

We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt

May 24
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt

Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet

Mar 09

Will Ultragenyx Pharmaceutical (NASDAQ:RARE) Spend Its Cash Wisely?

Feb 01
Will Ultragenyx Pharmaceutical (NASDAQ:RARE) Spend Its Cash Wisely?

There's No Escaping Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Muted Revenues Despite A 28% Share Price Rise

Dec 28
There's No Escaping Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Muted Revenues Despite A 28% Share Price Rise

Is There An Opportunity With Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 47% Undervaluation?

Sep 12
Is There An Opportunity With Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 47% Undervaluation?

An Intrinsic Calculation For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Suggests It's 50% Undervalued

May 24
An Intrinsic Calculation For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Suggests It's 50% Undervalued

Improved Revenues Required Before Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Find Their Feet

Apr 17
Improved Revenues Required Before Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Find Their Feet

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 33% Below Their Intrinsic Value Estimate

Feb 18
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 33% Below Their Intrinsic Value Estimate

CEO報酬分析

Ultragenyx Pharmaceutical の収益と比較して、Emil Kakkis の報酬はどのように変化したか？
日付総報酬給与会社業績
Sep 30 2024n/an/a

-US$559m

Jun 30 2024n/an/a

-US$585m

Mar 31 2024n/an/a

-US$613m

Dec 31 2023US$13mUS$824k

-US$607m

Sep 30 2023n/an/a

-US$635m

Jun 30 2023n/an/a

-US$721m

Mar 31 2023n/an/a

-US$719m

Dec 31 2022US$12mUS$796k

-US$707m

Sep 30 2022n/an/a

-US$678m

Jun 30 2022n/an/a

-US$506m

Mar 31 2022n/an/a

-US$470m

Dec 31 2021US$10mUS$769k

-US$454m

Sep 30 2021n/an/a

-US$356m

Jun 30 2021n/an/a

-US$351m

Mar 31 2021n/an/a

-US$204m

Dec 31 2020US$5mUS$759k

-US$187m

Sep 30 2020n/an/a

-US$256m

Jun 30 2020n/an/a

-US$301m

Mar 31 2020n/an/a

-US$425m

Dec 31 2019US$7mUS$714k

-US$403m

Sep 30 2019n/an/a

-US$397m

Jun 30 2019n/an/a

-US$371m

Mar 31 2019n/an/a

-US$325m

Dec 31 2018US$5mUS$680k

-US$198m

Sep 30 2018n/an/a

-US$192m

Jun 30 2018n/an/a

-US$183m

Mar 31 2018n/an/a

-US$204m

Dec 31 2017US$7mUS$638k

-US$302m

報酬と市場: Emilの 総報酬 ($USD 13.08M ) は、 US市場 ($USD 6.60M ) の同規模の企業の平均を上回っています。

報酬と収益: Emilの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Emil Kakkis (64 yo)

14.6yrs

在職期間

US$13,077,993

報酬

Dr. Emil D. Kakkis, M.D., Ph D., is Executive Director of Amlogenyx Inc. Dr. Kakkis has been a Director of Actio Biosciences Inc. since July 2024. He is Venture Advisor of Forge Life Science Partners.He i...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Emil Kakkis
Founder14.6yrsUS$13.08m2.91%
$ 123.6m
Howard Horn
Executive VP of Corporate Strategy & CFO1.1yrsUS$5.94m0.014%
$ 580.9k
Karah Parschauer
Chief Legal Officer & Executive VP of Corporate Affairs8.4yrsUS$4.04m0.017%
$ 704.5k
John Pinion
Chief Quality Operations Officer & Executive VP of Translational Sciences9.3yrsUS$4.05m0.050%
$ 2.1m
Erik Harris
Executive VP & Chief Commercial Officerno dataUS$4.07m0.025%
$ 1.1m
Theodore Huizenga
Senior VP10.8yrsデータなし0.019%
$ 818.7k
Ernie Meyer
Chief Human Resources Officer & Executive VP4.2yrsデータなしデータなし
Thomas Kassberg
Chief Business Officer & Executive VP13yrsUS$2.46m0.23%
$ 9.7m
Vimal Srivastava
Senior Vice President of Business Development & Alliance Management6.7yrsデータなしデータなし
Dennis Huang
Chief Technical Operations Officer and Executive VP of Gene Therapy Research & Development9.5yrsUS$4.24m0.044%
$ 1.9m
Aaron Olsen
Senior Vice President of Corporate Strategy & Financeno dataデータなしデータなし
Eric Crombez
Chief Medical Officer & Executive VP1.5yrsデータなし0.020%
$ 845.9k

8.9yrs

平均在職期間

58yo

平均年齢

経験豊富な経営陣: RAREの経営陣は経験豊富で経験豊富です（平均在職期間は8.9年）。

取締役

名称ポジション在職期間報酬所有権
Emil Kakkis
Founder14.6yrsUS$13.08m2.91%
$ 123.6m
Daniel Welch
Independent Non-Executive Chairman9.6yrsUS$499.89k0.023%
$ 994.1k
Matthew Fust
Independent Director10.8yrsUS$479.89k0.016%
$ 683.7k
Shehnaaz Suliman
Independent Director5.8yrsUS$466.89k0.016%
$ 683.7k
Deborah Dunsire
Independent Director7.6yrsUS$459.89k0.021%
$ 907.9k
Corazon Sanders
Independent Director3.4yrsUS$469.39k0.0058%
$ 245.9k
Michael Narachi
Independent Director9.8yrsUS$482.39k0.023%
$ 994.1k
Amrit Ray
Independent Director2.6yrsUS$460.39k0.011%
$ 486.7k

8.6yrs

平均在職期間

63yo

平均年齢

経験豊富なボード: RAREの 取締役会 は 経験豊富 であると考えられます ( 8.6年の平均在任期間)。